Please assess the completion status of the following clinical trial:

Trial Title: EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with established atrial fibrillation (AF) and bradycardia on long term (\>3 weeks) therapeutic oral anticoagulant (OAC) with warfarin or another OAC who are undergoing new pacemaker system implant or existing pacemaker system revision.~* Subjects with newly detected bradycardia -tachycardia syndrome and AF who have been recently (less than 3 weeks) started on warfarin, have a therapeutic international normalized ratio (INR) and no thrombus on trans-esophageal echocardiogram (TEE) who are undergoing a new pacemaker system implant or revision.~* Subjects with AF and ventricular tachyarrhythmias (VT or VF) or acquired structural heart disease who are candidates for implantable cardioverter-defibrillator (ICD) therapy and are on long term (\>3 weeks) therapeutic OAC with warfarin or another OAC who are undergoing new ICD system implant or existing ICD system revision.~* Subjects with newly detected AF with VT or VF who have been recently (less than 3 weeks) started on warfarin, have a therapeutic INR and no thrombus on TEE who are undergoing ICD system implant or revision~Exclusion Criteria:~* Clinically significant valvular heart disease~* Subjects requiring cardiovascular implantable electrical device (CIED) lead extraction e.g. for device site infection, endocarditis, leads under advisory or other conditions warranting lead(s) system extraction.~* Recent (\<1 month) myocardial infarction~* Documented left atrial (LA) thrombus on TEE~* Contraindications to anticoagulant therapy or adverse event with prior warfarin or edoxaban therapy~* Creatinine clearance \<30ml/min or \>95 ml/min~* Hepatic disease, advanced~* Recent stroke (\<3 months) or thromboembolic event~* Recent (\<3months) intracranial or other major bleeding event~* Use of concomitant dual antiplatelet therapy or other oral, subcutaneous or parenteral anticoagulant therapy~* Subjects on warfarin without therapeutic INR levels before study entry~* Subjects with other clinically significant medical condition~* Subjects with life expectancy \< 1 year~* Lead extraction procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edoxaban (Type: EXPERIMENTAL): Edoxaban 30 or 60 mg
- Warfarin (Type: ACTIVE_COMPARATOR): Warfarin 1 -1 0 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).